60526-69-4

Upstream product

• 91-10-1 1,3-dimethoxy-2-hydroxy-benzene 
• 628-44-4 2-methyl-2-octanol 

Downstream Products

• 866398-16-5 trifluoromethanesulfonic acid 4-(1,1-dimethylheptyl)-2,6-dimethoxyphenyl ester 
• 60526-75-2 4-(1',1'-dimethylheptyl)-2,6-dimethoxyphenyl diethylphosphate 
• 87613-50-1 3-(1,1-dimethylheptyl)-5-methoxyphenol 
• 181764-33-0 1-bromo-4-(1,1-dimethylheptyl)-2-methoxybenzene 
• 866398-21-2 1-(1,1-dimethylheptyl)-3-methoxybenzene 
• 83002-04-4 CP 55,940 
• 60526-81-0 1-(1',1'-dimethylheptyl)-3,5-dimethoxybenzene 
• 866398-07-4 (7R,8R)-7-[4-(1,1-dimethylheptyl)-2-methoxyphenyl]-8-(2-[1,3]dioxolan-2-ylethyl)-1,4-dioxaspiro[4,5]decane 
• 866398-09-6 3-{(7R,8R)-7-[4-(1,1-dimethylheptyl)-2-methoxyphenyl]-1,4-dioxaspiro[4,5]dec-8-yl}propan-1-ol 
• 866398-05-2 (1R,4R,5R,8S)-4-[4-(1,1-dimethylheptyl)-2-methoxyphenyl]-8-methoxymethoxybicyclo[3.3.1]non-3-en-2-one 
• 866398-11-0 (1R,3R,4R)-3-[4-(1,1-dimethylheptyl)-2-methoxyphenyl]-4-(3-hydroxypropyl)cyclohexanol 
• 866398-19-8 trifluoromethanesulfonic acid 3-(1,1-dimethylheptyl)-5-methoxyphenyl ester 

Relevant academic research and scientific papers

METHODS AND COMPOSITIONS RELATING TO ULTRAPURE 5-(1,1-DIMETHYLHEPTYL)-RESORCINOL

The invention provides methods and compositions relating to an ultrapure formulation of 5-(1,1-dimethylheptyl)-resorcinol (ultrapure DMHR). The invention features methods for making ultrapure DMHR, including methods that minimize the production of unwanted side products (e.g., the production of homologous alkyl-chain impurities). The invention also features methods of making cannabinoids, such as (6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyl-2-octanyl)-6a,7,10,10a-tetrahydro-6H-benzo[c]chromene-9-carboxylic acid (ajulemic acid), using ultrapure DMHR, including methods that minimize the production of unwanted side products (e.g., the production of homologous alkyl-chain impurities) in the resulting cannabinoid preparation.

Expedient synthesis of potent cannabinoid receptor agonist (-)-CP55,940

(Chemical Equation Presented) A stereocontrolled synthesis of (-)-CP55,940, a potent cannabinoid receptor agonist, has been attained using a novel aldolization/retroaldolization interconversion strategy, in which a temporarily generated chiral aldol motif plays essential roles.

High enantiomeric purity dexanabinol for pharmaceutical compositions

The present invention relates to a synthetic cannabinoid, dexanabinol, of enantiomeric purity in excess of 99.90%, or to a pharmaceutically acceptable salt, ester or solvate of said compound. The present invention also relates to pharmaceutical grade compositions comprising said compound of high enantiomeric purity, and uses thereof for prevention and treatment of neurological disorders, chronic degenerative diseases, CNS poisoning, cognitive impairment, inflammatory diseases or disorders, autoimmune diseases or disorders, pain, emesis, glaucoma and wasting syndromes.

5-(Tertiary alkyl) resorcinol preparation and intermediates therefor

2,6-Dimethoxyphenol reacts with a tertiary carbinol in the presence of an acid to provide exclusively a 1-hydroxy-2,6-dimethoxy-4-tertiary alkyl)benzene, which when reacted with a halogenated disubstituted phosphite affords a 2,6-dimethoxy-4-tertiary alkyl)phenyl disubstituted phosphate. Reduction of the phenyl phosphate derivative by reaction with an alkali metal affords a 1-(tertiary alkyl)-3,5-dimethoxybenzene, which upon reaction with a demethylating agent provides a 5-(tertiary alkyl)resorcinol.